Pleural Biopsy Market Trends and Forecast
The future of the global pleural biopsy market looks promising with opportunities in the hospitals, diagnostics laboratories, and cancer research institutes markets. The global pleural biopsy market is expected to grow with a CAGR of 3.5% from 2025 to 2031. The major drivers for this market are the rising prevalence of lung cancer and respiratory diseases, the advancements in diagnostic technologies, and the aging global population.
• Lucintel forecasts that, within the type category, malignancy is expected to witness the highest growth over the forecast period due to importance in staging and targeted treatment, higher diagnostic demand.
• Within the application category, hospitals is expected to witness the highest growth due to primary setting for cancer diagnosis and treatment.
• In terms of region, North America is expected to witness the highest growth over the forecast period due to high healthcare spending, rising awareness and early diagnosis.
Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.
Emerging Trends in the Pleural Biopsy Market
The pleural biopsy market is evolving with several emerging trends that are reshaping the landscape. These trends are driven by technological advancements, improved diagnostic capabilities, and the growing demand for patient-centered care.
• Minimally Invasive Techniques: There is a clear trend toward the use of minimally invasive pleural biopsy techniques, such as VATS and CT-guided biopsies, which reduce patient discomfort and recovery time. These procedures allow for better precision in obtaining tissue samples, leading to more accurate diagnoses. This trend is particularly important for patients with lung cancer, where early diagnosis is crucial for treatment outcomes.
• Integration with Precision Medicine: The integration of pleural biopsy with precision medicine is a growing trend. By combining tissue samples obtained through pleural biopsies with molecular and genetic profiling, clinicians can provide more personalized treatment options for patients. This trend is particularly prominent in oncology, where understanding the genetic makeup of tumors helps in selecting targeted therapies, improving patient prognosis and treatment effectiveness.
• Adoption of Liquid Biopsy Technologies: Liquid biopsy, a non-invasive procedure that analyzes blood samples for genetic material from tumors, is increasingly being used in conjunction with traditional pleural biopsies. This emerging trend allows for early detection and monitoring of lung cancer and other pleural diseases. Liquid biopsies provide a complementary diagnostic tool that enhances the accuracy of pleural biopsy results and provides continuous monitoring of disease progression.
• Technological Advancements in Imaging Techniques: The pleural biopsy market is benefiting from advancements in imaging technologies such as high-definition CT scans and ultrasound, which provide better visualization of the pleural space. These innovations allow for more precise needle placement, increasing the success rate of biopsy procedures and reducing complications. These advanced imaging techniques are also contributing to the growing use of image-guided biopsies in clinical practice.
• Increased Focus on Early Diagnosis and Early Stage Detection: There is a growing focus on early-stage detection of pleural diseases, especially lung cancer, to improve patient outcomes. With improved diagnostic tools, such as enhanced imaging and liquid biopsies, clinicians can detect diseases in their early stages, leading to better treatment options and survival rates. This trend is driving the demand for pleural biopsy procedures as part of routine screening and diagnostic protocols for high-risk patients.
These emerging trends are transforming the pleural biopsy market, making diagnostic procedures more precise, patient-friendly, and integrated with personalized treatment approaches. As technology advances and the focus shifts toward early detection and targeted therapies, the pleural biopsy market is expected to continue evolving, offering improved outcomes for patients and greater efficiency in healthcare systems.
Recent Development in the Pleural Biopsy Market
Several key developments have shaped the pleural biopsy market, including technological advancements, increased adoption of minimally invasive techniques, and the integration of precision medicine into clinical practice.
• Adoption of Minimally Invasive Techniques: Minimally invasive pleural biopsy techniques, such as VATS and CT-guided biopsies, have gained traction due to their ability to reduce patient trauma and recovery time. These procedures are increasingly being adopted in hospitals worldwide, making pleural biopsy more accessible and effective. They allow for better precision and have become the standard of care for diagnosing lung cancer and other pleural conditions.
• Integration with Precision Medicine and Molecular Diagnostics: The integration of pleural biopsy with molecular diagnostics and precision medicine is a major development. By analyzing genetic and molecular data from biopsy samples, clinicians can personalize treatment plans, especially for cancer patients. This approach enhances the effectiveness of treatment and improves patient outcomes, positioning pleural biopsy as a crucial part of modern oncology.
• Advancements in Imaging Technologies: The pleural biopsy market is benefitting from the rapid advancements in imaging technologies, such as high-resolution CT scans and real-time ultrasound. These technologies improve the accuracy of biopsy needle placement and reduce the risk of complications. As imaging systems become more sophisticated, they enhance the effectiveness and safety of pleural biopsy procedures.
• Growth in Liquid Biopsy as a Complementary Tool: Liquid biopsy technologies, which analyze blood samples for tumor DNA, have gained attention as a complementary tool for pleural biopsy. This technology allows for early detection and monitoring of pleural diseases like lung cancer. The integration of liquid biopsy with traditional pleural biopsy enhances diagnostic accuracy and provides additional insights into disease progression, driving growth in the market.
• Increased Focus on Early Detection of Lung Cancer: There has been a significant increase in efforts to detect lung cancer and other pleural diseases at earlier stages. This trend is driving the adoption of pleural biopsy in routine clinical practice. Early-stage detection allows for more effective treatment options, improving survival rates. Enhanced imaging and the integration of liquid biopsy with pleural biopsy contribute to this trend.
These developments reflect the growing sophistication of pleural biopsy procedures, driven by technological advancements and the integration of precision medicine. As minimally invasive techniques become more common and imaging technologies improve, pleural biopsy is becoming a more accessible, effective, and patient-friendly diagnostic tool. The market is also evolving with complementary tools like liquid biopsy, enabling more accurate and timely diagnoses.
Strategic Growth Opportunities in the Pleural Biopsy Market
The pleural biopsy market presents several growth opportunities for companies focusing on key applications, ranging from technology innovations to expanding healthcare access.
• Expansion of Minimally Invasive Procedures: The shift toward minimally invasive procedures like VATS and CT-guided pleural biopsies presents a growth opportunity for companies developing advanced biopsy tools. These techniques offer numerous advantages, including shorter recovery times, lower complication rates, and greater precision. Companies that develop more efficient and cost-effective instruments for these procedures can capture a significant portion of the growing demand.
• Integration with Precision Medicine: The growing trend toward personalized medicine presents an opportunity for the pleural biopsy market. By integrating pleural biopsy with molecular diagnostics and genetic testing, companies can offer more precise diagnostic solutions. This integration enables clinicians to tailor treatment plans to individual patients, especially those with cancer, creating a significant opportunity for growth in precision oncology.
• Development of Liquid Biopsy Technologies: Liquid biopsy, which analyzes blood samples for tumor DNA, is emerging as a complementary diagnostic tool to pleural biopsy. Companies investing in liquid biopsy technologies can capitalize on their potential to improve early diagnosis and monitoring of pleural diseases like lung cancer. The integration of liquid biopsy with traditional pleural biopsy enhances diagnostic accuracy, creating new market opportunities.
• Growth in Emerging Markets: Emerging markets, particularly in Asia and Africa, present significant growth opportunities due to increasing healthcare access and rising awareness of lung diseases. Expanding access to pleural biopsy procedures and associated diagnostic tools in these regions can drive market growth. Companies that focus on affordability and local healthcare partnerships can tap into these underserved markets.
• Technological Advancements in Imaging and Biopsy Tools: As imaging technologies like high-definition CT scans and real-time ultrasound evolve, they create opportunities for companies to develop more precise biopsy tools. Enhanced imaging leads to better placement of biopsy needles, reducing complications and improving diagnostic accuracy. This trend offers significant growth potential for manufacturers of imaging and biopsy devices.
These strategic growth opportunities, ranging from technological innovations to market expansion, will shape the future of the pleural biopsy market. Companies that leverage these trends, such as the development of advanced imaging tools and the integration of precision medicine, will be well-positioned to capture growing demand and drive market growth.
Pleural Biopsy Market Driver and Challenges
The pleural biopsy market is shaped by several drivers and challenges that impact its growth, including technological, economic, and regulatory factors.
The factors responsible for driving the Pleural Biopsy market include:
1. Increasing Incidence of Lung Diseases and Cancer: The rising incidence of lung diseases and cancers is a primary driver of the pleural biopsy market. As more people are diagnosed with conditions like lung cancer, pleural biopsies are essential for accurate diagnosis and staging, driving demand for these procedures.
2. Advancements in Minimally Invasive Techniques: The shift toward minimally invasive techniques in pleural biopsy procedures, such as VATS and CT-guided biopsies, is significantly driving market growth. These procedures reduce patient discomfort and recovery times, making them more attractive to both patients and healthcare providers.
3. Technological Innovations in Imaging and Diagnostics: Innovations in imaging technologies, such as high-definition CT scans and ultrasound, have enhanced the accuracy and safety of pleural biopsy procedures. These advancements increase the effectiveness of diagnostic procedures, driving demand for pleural biopsy tools and technologies.
4. Integration with Precision Medicine: The integration of pleural biopsy with precision medicine and molecular diagnostics is a key driver. This approach allows for more personalized treatment plans, particularly for cancer patients, which has increased the demand for pleural biopsy as part of comprehensive diagnostic and treatment regimens.
5. Growing Awareness and Early Detection Efforts: There is a growing focus on early detection of lung cancer and other pleural diseases. As healthcare systems prioritize early diagnosis, pleural biopsy is becoming a standard part of the diagnostic toolkit, driving its growth in clinical practice.
Challenges in the Pleural Biopsy market are:
1. High Cost of Procedures and Tools: The high cost of pleural biopsy procedures and diagnostic tools, particularly in advanced imaging technologies, poses a significant challenge. This may limit access to these procedures in low-income regions and contribute to disparities in healthcare access.
2. Limited Access in Rural and Developing Regions: While pleural biopsy procedures are advancing in developed countries, their availability is limited in rural and developing regions. Lack of infrastructure and trained personnel can restrict access to these procedures, hindering market growth in some areas.
3. Regulatory and Reimbursement Issues: Regulatory challenges, particularly in emerging markets, can delay the adoption of new technologies and procedures in pleural biopsy. Additionally, reimbursement policies may limit patient access to advanced biopsy procedures, posing a barrier to market growth.
The pleural biopsy market is driven by factors such as the increasing incidence of lung diseases, advancements in diagnostic techniques, and integration with precision medicine. However, challenges such as high costs, limited access in certain regions, and regulatory hurdles remain obstacles. Addressing these challenges while leveraging key drivers will be essential for continued market growth.
List of Pleural Biopsy Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies pleural biopsy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pleural biopsy companies profiled in this report include-
• Olympus
• Boston Scientific
• B. Braun Melsungen
• KARL STORZ
• Medtronic
• Fujifilm
• Cardinal Health
Pleural Biopsy Market by Segment
The study includes a forecast for the global pleural biopsy market by type, application, and region.
Pleural Biopsy Market by Type [Value from 2019 to 2031]:
• Malignancy
• Granulomatous
• Lupus
Pleural Biopsy Market by Application [Value from 2019 to 2031]:
• Hospitals
• Diagnostics Laboratories
• Cancer Research Institutes
Pleural Biopsy Market by Region [Value from 2019 to 2031]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Pleural Biopsy Market
The pleural biopsy market is experiencing advancements due to increasing cases of pleural diseases, advancements in medical technology, and the growing demand for minimally invasive diagnostic procedures. Pleural biopsy, a procedure used to obtain tissue samples from the pleural space for diagnosing diseases such as cancer, infections, or inflammatory conditions, is crucial for effective disease management. With evolving healthcare systems in countries like the United States, China, Germany, India, and Japan, the market is seeing various developments aimed at improving diagnostic accuracy, patient comfort, and clinical outcomes. The following highlights key developments in these regions.
• United States: The United States has seen significant growth in the pleural biopsy market, driven by the increasing prevalence of lung diseases and cancer. Advances in biopsy techniques, such as image-guided biopsies and minimally invasive procedures like video-assisted thoracoscopic surgery (VATS), have improved diagnostic accuracy and reduced patient recovery time. In addition, there has been a rise in the use of liquid biopsy technologies to complement pleural biopsy. U.S. healthcare institutions are increasingly adopting these advanced techniques to improve early-stage cancer detection and enhance patient care. Reimbursement policies and insurance coverage for pleural biopsy procedures have also expanded, driving market growth.
• China: China is witnessing rapid development in the pleural biopsy market due to the rising incidence of respiratory diseases and lung cancer. The country’s healthcare infrastructure is advancing, with a focus on improving diagnostic capabilities in hospitals and clinics. Image-guided pleural biopsies, such as CT-guided and ultrasound-guided techniques, are gaining popularity. However, affordability and access to these advanced procedures in rural areas remain a challenge. Despite this, increasing government initiatives to improve healthcare accessibility and the growing demand for early diagnostic tools are driving growth. The adoption of minimally invasive procedures is expected to further enhance the market in China.
• Germany: Germany has been a leader in the pleural biopsy market in Europe, characterized by its advanced healthcare system and high levels of medical research. The adoption of minimally invasive techniques like VATS and CT-guided pleural biopsies is widespread in German hospitals. Additionally, there is an increasing trend towards the use of precision medicine, where pleural biopsy results are integrated with genetic and molecular data to tailor treatment plans for patients, particularly those with cancer. Germany’s focus on high-quality healthcare delivery and state-of-the-art diagnostic technologies positions it as a key player in the pleural biopsy market.
• India: India’s pleural biopsy market is witnessing growth due to the rising incidence of lung cancer, tuberculosis, and other respiratory diseases. While image-guided biopsy techniques are becoming more common in urban hospitals, accessibility to advanced diagnostic tools remains limited in rural areas. The adoption of minimally invasive procedures is gradually increasing, driven by growing awareness and healthcare infrastructure improvements. Despite challenges such as high costs and limited insurance coverage, India’s healthcare sector is increasingly integrating advanced diagnostic techniques like VATS and CT-guided pleural biopsy, resulting in better patient outcomes and driving the market’s growth.
• Japan: Japan has a well-established pleural biopsy market with a strong focus on advanced diagnostic procedures and precision medicine. The country has seen a rise in the use of minimally invasive pleural biopsy techniques, especially VATS and ultrasound-guided biopsies, as part of efforts to reduce patient trauma and recovery times. Japan’s aging population is a significant factor driving the demand for pleural biopsy, especially for lung cancer detection. Additionally, the country’s healthcare system is focused on early detection and personalized treatment plans, boosting the integration of pleural biopsies with other diagnostic tools like liquid biopsies, driving further growth in the market.
Features of the Global Pleural Biopsy Market
Market Size Estimates: Pleural biopsy market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2024 to 2031) by various segments and regions.
Segmentation Analysis: Pleural biopsy market size by type, application, and region in terms of value ($B).
Regional Analysis: Pleural biopsy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the pleural biopsy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pleural biopsy market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for pleural biopsy market?
Answer: The global pleural biopsy market is expected to grow with a CAGR of 3.5% from 2025 to 2031.
Q2. What are the major drivers influencing the growth of the pleural biopsy market?
Answer: The major drivers for this market are the rising prevalence of lung cancer and respiratory diseases, the advancements in diagnostic technologies, and the aging global population.
Q3. What are the major segments for pleural biopsy market?
Answer: The future of the pleural biopsy market looks promising with opportunities in the hospitals, diagnostics laboratories, and cancer research institutes markets.
Q4. Who are the key pleural biopsy market companies?
Answer: Some of the key pleural biopsy companies are as follows:
• Olympus
• Boston Scientific
• B. Braun Melsungen
• KARL STORZ
• Medtronic
• Fujifilm
• Cardinal Health
Q5. Which pleural biopsy market segment will be the largest in future?
Answer: Lucintel forecasts that malignancy is expected to witness the highest growth over the forecast period due to importance in staging and targeted treatment, higher diagnostic demand.
Q6. In pleural biopsy market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness the highest growth over the forecast period due to high healthcare spending, rising awareness and early diagnosis.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the pleural biopsy market by type (malignancy, granulomatous, and lupus), application (hospitals, diagnostics laboratories, and cancer research institutes), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Pleural Biopsy Market, Pleural Biopsy Market Size, Pleural Biopsy Market Growth, Pleural Biopsy Market Analysis, Pleural Biopsy Market Report, Pleural Biopsy Market Share, Pleural Biopsy Market Trends, Pleural Biopsy Market Forecast, Pleural Biopsy Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.